Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art ReviewVisa övriga samt affilieringar
2020 (Engelska)Ingår i: Journal of the American College of Cardiology, ISSN 0735-1097, E-ISSN 1558-3597, Vol. 76, nr 15, s. 1777-1794Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]
Viral respiratory infections are risk factors for cardiovascular disease (CVD). Underlying CVD is also associated with an increased risk of complications following viral respiratory infections, including increased morbidity, mortality, and health care utilization. Globally, these phenomena are observed with seasonal influenza and with the current coronavirus disease 2019 (COVID-19) pandemic. Persons with CVD represent an important target population for respiratory virus vaccines, with capacity developed within 3 large ongoing influenza vaccine cardiovascular outcomes trials to determine the potential cardioprotective effects of influenza vaccines. In the context of COVID-19, these international trial networks may be uniquely positioned to redeploy infrastructure to study therapies for primary and secondary prevention of COVID-19. Here, we describe mechanistic links between influenza and COVID-19 infection and the risk of acute cardiovascular events, summarize the data to date on the potential cardioprotective effects of influenza vaccines, and describe the ongoing influenza vaccine cardiovascular outcomes trials, highlighting important lessons learned that are applicable to COVID-19.
Ort, förlag, år, upplaga, sidor
Elsevier, 2020. Vol. 76, nr 15, s. 1777-1794
Nyckelord [en]
Acute myocardial infarction, cardioprotection, heart failure, influenza vaccination
Nationell ämneskategori
Kardiologi och kardiovaskulära sjukdomar
Identifikatorer
URN: urn:nbn:se:oru:diva-86386DOI: 10.1016/j.jacc.2020.08.028ISI: 000579524400009PubMedID: 33032740Scopus ID: 2-s2.0-85091633841OAI: oai:DiVA.org:oru-86386DiVA, id: diva2:1475481
Forskningsfinansiär
AstraZeneca
Anmärkning
Funding Agencies:
University of Toronto MD/PhD studentship award
Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research
CANHEART SPOR Graduate Studentship Award
Secretaria de Educacion Superior, Ciencia, Tecnologia e Innovacion (SENESCYT) 2018 Programa de Becas Internacionales
Sanofi Pasteur
Merck & Company
Örebro University, Faculty of Health, Department of Cardiology
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
Amgen
Alnylam
Lone Star Heart
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Heart Lung & Blood Institute (NHLBI)
Theracos
Heart and Stroke Foundation of Canada National New Investigator-Ontario Clinician Scientist Award
Ontario Ministry of Research, Innovation and Science Early Researcher Award
University of Toronto
Department of Medicine, Women's College Hospital
Novartis
Sanofi
Pfizer
Seqirus
Bellerophon
Bayer AG
Bristol-Myers Squibb
Celladon
Cytokinetics
Eidos
Gilead Sciences
GlaxoSmithKline
Ionis
Mesoblast
MyoKardia
2020-10-132020-10-132025-02-10Bibliografiskt granskad